Search hospitals > Ohio > Barberton
Summa Health System - Barberton Campus
Claim this profileBarberton, Ohio 44203
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Prostate Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
121 reported clinical trials
2 medical researchers
Summary
Summa Health System - Barberton Campus is a medical facility located in Barberton, Ohio. This center is recognized for care of Breast Cancer, Cancer, Prostate Cancer, Lung Cancer, Adenocarcinoma and other specialties. Summa Health System - Barberton Campus is involved with conducting 121 clinical trials across 175 conditions. There are 2 research doctors associated with this hospital, such as Bradley T. Clifford and Desiree E. Doncals.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
2Cancer
Global LeaderStage III
Stage IV
p16 positive
Top PIs
Bradley T. CliffordSumma Health System - Akron Campus1 year of reported clinical research
Studies Cancer
Studies Breast Cancer
17 reported clinical trials
38 drugs studied
Desiree E. DoncalsSumma Health System - Akron Campus3 years of reported clinical research
Studies Cancer
Studies Breast Cancer
7 reported clinical trials
34 drugs studied
Clinical Trials running at Summa Health System - Barberton Campus
Breast Cancer
Squamous Cell Carcinoma
Prostate Cancer
Recurrence
Cancer
Laryngeal Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Prostate Adenocarcinoma
Non-Small Cell Lung Cancer
Lung Cancer
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Summa Health System - Barberton Campus?
Summa Health System - Barberton Campus is a medical facility located in Barberton, Ohio. This center is recognized for care of Breast Cancer, Cancer, Prostate Cancer, Lung Cancer, Adenocarcinoma and other specialties. Summa Health System - Barberton Campus is involved with conducting 121 clinical trials across 175 conditions. There are 2 research doctors associated with this hospital, such as Bradley T. Clifford and Desiree E. Doncals.